Amy Lerman
MemberEpstein Becker GreenAmy Lerman is a Member of Epstein Becker Green’s Health Care and Life Sciences team and is based in the firm’s Washington, DC office. Amy advises a wide range of clients—including durable medical equipment (DME) suppliers, digital health companies, and other health care innovators—on complex legal, regulatory, and compliance matters. Amy counsels clients on government investigations, audits, and allegations involving fraud, false claims, and related compliance risks. She provides guidance on a broad scope of regulatory questions and helps clients develop and strengthen corporate compliance program infrastructures. Clients regularly turn to Amy for insight into legal and reimbursement issues under Medicare, Medicaid, and other third-party payer programs.
Amy is particularly focused on supporting companies navigating phases of innovation, growth, and operational evolution. She helps emerging and disruptive health care companies align their business models with the evolving regulatory landscape and anticipate policy shifts. In addition, Amy is the lead author of the firm’s Telemental Health Laws app, a comprehensive survey of state telehealth laws, regulations, and policies for mental and behavioral health practitioners and stakeholders across all 50 states, the District of Columbia, and Puerto Rico.
AU02: Innovate Responsibly: Compliance Strategies that Empower (and Don’t Hinder) DME Growth
Innovation in the DME industry is no longer optional. It is a competitive necessity. Yet, whether you are launching a digital ordering platform, inte…Innovation in the DME industry is no longer optional. It is a competitive necessity. Yet, whether you are launching a digital ordering platform, integrating with telehealth partners, or redesigning patient onboarding functions, regulatory gray areas…Innovation in the DME industry is no longer optional. It is a competitive necessity. Yet, whether you are launching a digital ordering platform, integrating with telehealth partners, or redesigning patient onboarding functions, regulatory gray areas are unavoidable. How should you approach compliance when innovation can outpace regulation? This session is for innovators—founders, growth leaders, product teams, and forward-thinking executives—who are pushing the DME industry forward. Our panel of legal, compliance, and industry experts will offer practical, real-world guidance on how to strategically build your compliance infrastructure—how to integrate compliance best practices with operational scaling—to foster trust and mitigate potential legal and reputational risks. You’ll walk away with a compliance mindset that aligns with your business goals—so you can innovate boldly and within legal guardrails. Speakers will discuss: Why innovators should care about compliance Common compliance “hot zones”— where innovation meets regulation Structuring partnerships compliantly Scaling for effective compliance — compliance that does not kill growth Enforcement trends and future risk Learning Objectives: After attending this session, participants will be able to: Spot common compliance risk areas for fast-growing or tech-forward DME businesses and learn strategies for mitigation. Appreciate key considerations in designing compliant workflows (e.g., e-prescribing, patient intake, delivery tracking) that meet both user needs and regulatory standards. Evaluate partnership opportunities, particularly those with potential referral sources, through a compliance lens and without killing the deal. Leverage compliance as a value-add in product development, fundraising, and go-to-market strategies, especially when engaging with payers or institutional partners. Design and implement scalable internal controls that support growth-stage operations without stalling progress.Show MoreClick the title to see all details
